Dr. Scott N. Gettinger, MD
Medical Oncology (Medical Oncology Physician)
800 Howard Ave, Yale Physicians Building - 2nd Floor
New Haven, CT 06519
- Medicare participating
At a glance
- Medical school
- State University of New York at Stony Brook, School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 127
Licensed in Connecticut since 2005, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: State University of New York at Stony Brook, School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CT license 043302 (first issued 2005; active) -
Hematology (Internal Medicine) Physician
CT license 043302 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Bridgeport Hospital Bridgeport, CT
- Greenwich Hospital Association - Greenwich, CT
- Lawrence & Memorial Hospital New London, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 127
- Services billed
- 546
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 270 | 84 |
| Established patient office or other outpatient visit, 40-54 minutes | 106 | 52 |
| Telephone medical discussion with physician, 11-20 minutes | 37 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in New Haven, CT | 48 |
| Eliquis (apixaban) Other prescribers in New Haven, CT | 40 |
| Prochlorperazine Maleate Other prescribers in New Haven, CT | 28 |
| Prednisone Other prescribers in New Haven, CT | 25 |
| Oxycodone Hcl Other prescribers in New Haven, CT | 23 |
| Ondansetron Odt (ondansetron) Other prescribers in New Haven, CT | 22 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in New Haven, CT | 16 |
| Folic Acid Other prescribers in New Haven, CT | 14 |
| Pantoprazole Sodium Other prescribers in New Haven, CT | 13 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New Haven, CT | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $19.70 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $19.70 |
|---|
| Food and Beverage | $19.70 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $329,604 in research payments for these studies, mostly to the institutions running them.
- STUDY NAME#A phase II study of NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer
Merck Sharp & Dohme LLC - 2015-NIV-0383 A phase II study of ipilimumab and nivolumab in patients with advanced Non Small Cell Lung Cancer resistant to nivolumab monotherapy
E.r. Squibb & Sons, L.l.c. - Study name not reported
Iovance Biotherapeutics, Inc. - An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy
E.r. Squibb & Sons, L.l.c. - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Nave Stage IV or R…
E.r. Squibb & Sons, L.l.c. - A Phase 3b, Multicenter, Single-arm, Expanded Access Protocol of Tarlatamab (AMG 757) for the Treatment of Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.